Technology area: Biotechnology & Pharmaceuticals
25 pending office actions • 13 art units • 21 examiners • 0 of 25 (0%) have an AI response strategy ready • 31 patents granted in the last 365 days
Intervet Inc. has 29 pending office actions in Biotechnology & Pharmaceuticals. The portfolio spans 24 examiners and 13 art units, showing substantial distribution across examination personnel and technical groups.
ZEMAN, ROBERT A is the busiest examiner, with 2 pending matters. That assignment is small relative to the portfolio’s overall examiner footprint, so centralized prosecution guidance should be supplemented with matter-specific review across the different art units.
The breadth of the portfolio calls for tracking examiner correspondence, art-unit practices, and response timing at the individual application level. Coordination can identify recurring issues, but the data does not support treating the portfolio as a single examiner relationship.
Based on the USPTO statutory response window for each pending office action. 8 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 8 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 8 (32%) |
| §112 only | 1 (4%) |
| Double-patenting only | 1 (4%) |
| Double-patenting + other | 5 (20%) |
| Multi-statute (no §101) | 10 (40%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ZEMAN, ROBERT A | 2 | 54.2% | +27.9% |
| BOESEN, AGNIESZKA | 2 | 68.6% | +21.8% |
| ALLEN, MICHAEL D | 2 | 31.9% | +48.8% |
| DICKENS, AMELIA NICOLE | 2 | 47.2% | +21.6% |
| GANGLE, BRIAN J | 1 | 76.8% | +14.6% |
| CHESTNUT, BARRY A | 1 | 73.9% | +6.3% |
| SHIM, DAVID M. | 1 | 58.8% | +58.5% |
| MCINTOSH III, TRAVISS C | 1 | 73.3% | +14.1% |
| MAHADEVAN, JANAKI ANANTH | 1 | 0.0% | +0.0% |
| TRAN, ERIC | 1 | 69.8% | +19.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18335415 | SOLID ORAL PHARMACEUTICAL COMPOSITIONS FOR ISOXAZOLINE COMPOUNDS | BORALSKY, LUKE ALAN | 9d overdue |
| 18257420 | CONJUGATED T-2 TOXIN TO PROTECT AGAINST MYCOTOXICOSIS | MORGAN, BAILEY MICHELLE | 8d overdue |
| 18263211 | ANTIPARASITIC COMPOUNDS | SZNAIDMAN, MARCOS L | 9d |
| 18873753 | VACCINE FOR PROTECTION AGAINST LEPTOSPIRA SEROVAR ICTEROHAEMORRHAGIAE | ZEMAN, ROBERT A | — |
| 18723268 | STABLE EMULSIONS OF ANTIGENS | ALLEN, MICHAEL D | — |
| 18721947 | AN INJECTABLE PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF RESPIRATORY DISEASES IN ANIMALS | SHIM, DAVID M. | — |
| 18294592 | METHOD OF TREATING VETERINARY VIRAL DISEASES | MAHADEVAN, JANAKI ANANTH | — |
| 17775425 | A NOVEL VACCINE AGAINST HAEMOPHILUS PARASUIS | DICKENS, AMELIA NICOLE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17641031 | COMBINATION VACCINE FOR INTRADERMAL ADMINISTRATION | ZEMAN, ROBERT A | 34d |
| 18416336 | ISOXAZOLINE COMPOSITIONS AND THEIR USE AS ANTIPARASITICS | TRAN, ERIC | 41d |
| 19094116 | CONJUGATED DEOXYNIVALENOL TO PROTECT AGAINST MYCOTOXICOSIS | GANGLE, BRIAN J | — |
| 18873753 | VACCINE FOR PROTECTION AGAINST LEPTOSPIRA SEROVAR ICTEROHAEMORRHAGIAE | ZEMAN, ROBERT A | — |
| 18723259 | STABILISED LIQUID VACCINES OF LIVE VIRUSES | BOESEN, AGNIESZKA | — |
| 18723268 | STABLE EMULSIONS OF ANTIGENS | ALLEN, MICHAEL D | — |
| 18721947 | AN INJECTABLE PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF RESPIRATORY DISEASES IN ANIMALS | SHIM, DAVID M. | — |
| 18720093 | A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF OTIC INFECTIONS | MCINTOSH III, TRAVISS C | — |
| Art Unit | Apps |
|---|---|
| 1645 | 6 |
| 1672 | 4 |
| 1671 | 3 |
| 1693 | 2 |
| 1641 | 2 |
| 1626 | 1 |
| 1629 | 1 |
| 2663 | 1 |
| 1628 | 1 |
| 1624 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19094116 | CONJUGATED DEOXYNIVALENOL TO PROTECT AGAINST MYCOTOXICOSIS | GANGLE, BRIAN J | 1645 | §102§103DP | Non-Final OA | — | Pending | Mar 28, 2025 |
| 18873753 | VACCINE FOR PROTECTION AGAINST LEPTOSPIRA SEROVAR ICTEROHAEMORRHAGIAE | ZEMAN, ROBERT A | 1645 | §102§112 | Non-Final OA | — | Pending | Dec 11, 2024 |
| 18794860 | FELINE LEUKEMIA VIRUS VACCINE | CHESTNUT, BARRY A | 1672 | DP | Non-Final OA | — | Pending | Aug 05, 2024 |
| 18723259 | STABILISED LIQUID VACCINES OF LIVE VIRUSES | BOESEN, AGNIESZKA | 1672 | §103 | Non-Final OA | — | Pending | Jun 21, 2024 |
| 18723268 | STABLE EMULSIONS OF ANTIGENS | ALLEN, MICHAEL D | 1671 | §103§112 | Non-Final OA | — | Pending | Jun 21, 2024 |
| 18721947 | AN INJECTABLE PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF RESPIRATORY DISEASES IN ANIMALS | SHIM, DAVID M. | 1626 | §102§103§112Other | Non-Final OA | — | Pending | Jun 20, 2024 |
| 18720093 | A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF OTIC INFECTIONS | MCINTOSH III, TRAVISS C | 1693 | §103 | Non-Final OA | — | Pending | Jun 14, 2024 |
| 18702577 | A VACCINE FOR THE PROTECTION OF PIGLETS AGAINST SWINE INFLUENZA A VIRUS INFECTION | BOESEN, AGNIESZKA | 1672 | §102§103§112DP | Non-Final OA | — | Pending | Apr 18, 2024 |
| 18294592 | METHOD OF TREATING VETERINARY VIRAL DISEASES | MAHADEVAN, JANAKI ANANTH | 1693 | §102§103§112 | Non-Final OA | — | Pending | Feb 02, 2024 |
| 18416336 | ISOXAZOLINE COMPOSITIONS AND THEIR USE AS ANTIPARASITICS | TRAN, ERIC | 1629 | §103 | Non-Final OA | 41d | Pending | Jan 18, 2024 |
| 18570341 | METHOD AND SYSTEM FOR COUNTING BIRD PARASITES | MORSE, GREGORY ALLAN | 2663 | §103 | Final Rejection | — | Pending | Dec 14, 2023 |
| 18264446 | VACCINATION FOR PROTECTING POULTRY AGAINST A POULTRY PATHOGEN | LY, KRISTINA ELISABETH | 1641 | §102§103§112DP | Non-Final OA | — | Pending | Aug 07, 2023 |
| 18263211 | ANTIPARASITIC COMPOUNDS | SZNAIDMAN, MARCOS L | 1628 | §102§103 | Final Rejection | 9d | Pending | Jul 27, 2023 |
| 18335415 | SOLID ORAL PHARMACEUTICAL COMPOSITIONS FOR ISOXAZOLINE COMPOUNDS | BORALSKY, LUKE ALAN | 1624 | §102§112 | Non-Final OA | 9d overdue | Pending | Jun 15, 2023 |
| 18257420 | CONJUGATED T-2 TOXIN TO PROTECT AGAINST MYCOTOXICOSIS | MORGAN, BAILEY MICHELLE | 1645 | §103§112 | Final Rejection | 8d overdue | Pending | Jun 14, 2023 |
| 18253140 | METHOD OF TREATMENT OF PAIN THROUGH BUCCAL ADMINISTRATION OF FLUNIXIN | SOROUSH, LAYLA | 1622 | §103 | Final Rejection | — | Pending | May 16, 2023 |
| 18250106 | COMBINATION VACCINE FOR PROTECTING SWINE AGAINST VARIOUS DISORDERS | SZPERKA, MICHAEL EDWARD | 1641 | §103Other | Non-Final OA | 34d | Pending | Apr 21, 2023 |
| 18249419 | BACULOVIRUS EXPRESSION VECTOR | JADHAO, SAMADHAN JAISING | 1672 | §103 | Final Rejection | 5d overdue | Pending | Apr 18, 2023 |
| 17785223 | REASSORTED ISA VIRUS | ALLEN, MICHAEL D | 1671 | §112DP | Final Rejection | — | Pending | Jun 14, 2022 |
| 17783220 | PARASITE CONTROL IN RUMINANTS | MCMILLIAN, KARA RENITA | 1623 | §103 | Final Rejection | 38d overdue | Pending | Jun 07, 2022 |
| 17775425 | A NOVEL VACCINE AGAINST HAEMOPHILUS PARASUIS | DICKENS, AMELIA NICOLE | 1645 | §102§112 | Non-Final OA | — | Pending | May 09, 2022 |
| 17775428 | NOVEL VACCINE AGAINST HAEMOPHILUS PARASUIS | DICKENS, AMELIA NICOLE | 1645 | §102§112 | Non-Final OA | — | Pending | May 09, 2022 |
| 17641031 | COMBINATION VACCINE FOR INTRADERMAL ADMINISTRATION | ZEMAN, ROBERT A | 1645 | §112 | Final Rejection | 34d | Pending | Mar 07, 2022 |
| 17615961 | MDBK IRF3/IRF7 KNOCK OUT MUTANT CELL AND ITS USE FOR VACCINE PRODUCTION | SIFFORD, JEFFREY MARK | 1671 | §103§112 | Non-Final OA | — | Pending | Dec 02, 2021 |
| 16761670 | INJECTABLE ISOXAZOLINE PHARMACEUTICAL COMPOSITIONS AND THEIR USE AGAINST PARASITE INFESTATION | SAEED, ALI S | 1616 | §103DP | Non-Final OA | — | Pending | May 05, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialIntervet Inc. has 25 pending office actions as of October 2026, spread across 13 art units and 21 examiners.
Robert A Zeman has the most, with 2 of Intervet Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
